Karen A. Gelmon - Researcher Profile

Publications

2 shown

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Anthony W. Tolcher , Steven Sugarman , Karen A. Gelmon +7 more

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is direc...

1999 Journal of Clinical Oncology 266 citations

Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

Andrew Tutt , Judy E. Garber , Bella Kaufman +36 more

Among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after comp...

2021 New England Journal of Medicine 1483 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 1,749
Institution: Bristol-Myers Squibb (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-4111-2757

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.